Wutah pendapatan taun lumaku: Reata Pharma (RETA)

Reata Pharmaceuticals operates a business that is independent of economic cycles due to the inelastic demand for the treatment of rare pathologies. The 12-month year-over-year sales trend illustrates the expansion of Skyclarys in Europe and the resulting revenue growth. The value of reflects the most recent metric value. Market confidence is bolstered by the company's integration into the structure of a global leader and management's focus on scaling the product.
Reata Pharma (RETA) - rincian metrik lan laporan keuangan

Reata Pharmaceuticals (RETA) remains insulated from macroeconomic shocks due to its unique medical developments, making the year-over-year (LTM) gross revenue trend a key indicator of this defensive asset's resilience. This metric measures the relative change in trailing twelve-month rolling revenue, allowing investors to identify hidden cash flow deceleration between quarterly reports to minimize the risk of a deep capital drawdown.